Skip to main content
Top
Published in: Medical Oncology 1/2012

01-03-2012 | Original Paper

Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer

Authors: Motohiro Tamiya, Hidekazu Suzuki, Masashi Kobayashi, Shinji Sasada, Norio Okamoto, Naoko Morishita, Tomomi Yasue, Yuka Matsuura, Tomonori Hirashima, Ichiro Kawase

Published in: Medical Oncology | Issue 1/2012

Login to get access

Abstract

Bone metastasis is an important factor for determining the appropriate treatment for patients with lung cancer. The cross-linked N-terminal telopeptide of type I collagen (NTx) is a metabolite of type I collagen, the main constituent of the bone matrix. Urinary NTx is recognized as a useful marker of bone metastasis, but the application of serum NTx and its cutoff value for determining bone metastasis from lung cancer have not been characterized. We measured serum NTx by enzyme-linked immunosorbent assay of individuals who underwent staging during hospitalization for initial treatment of lung cancer in our department and compared the NTx levels with the presence of bone metastasis in staging. The study included 166 patients with lung cancer (128 men and 38 women), including 85 adenocarcinoma, 42 squamous cell carcinoma, 32 small-cell carcinoma, and 7 other cancer types. Bone metastasis was present in 73 cases. The average/median serum NTx of bone metastasis (+) and bone metastasis (−) was 27.8/23.8 and 17.1/16.5 nmol bone collagen equivalents/L, respectively. There was an intentional difference with P < 0.001. The cutoff value of the serum NTx level indicating bone metastasis from lung cancer was estimated using the receiver operating characteristics curve. The optimal cutoff value was found to be 22.0 (sensitivity: 61.6%, specificity: 89.2%). The results of univariate and multivariate analysis revealed that the serum NTx levels were significantly related to bone metastasis from lung cancer (P < 0.001). Measurement of serum NTx levels provides a simple diagnostic marker of bone metastasis from lung cancer.
Literature
1.
go back to reference Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal. 2004;34:827–32.PubMedCrossRef Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal. 2004;34:827–32.PubMedCrossRef
3.
go back to reference Perez DJ, et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 1983;2:613–6.PubMedCrossRef Perez DJ, et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 1983;2:613–6.PubMedCrossRef
4.
go back to reference Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92.PubMedCrossRef Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92.PubMedCrossRef
5.
go back to reference Pecherstorfer M, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995;80:97–103.PubMedCrossRef Pecherstorfer M, et al. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 1995;80:97–103.PubMedCrossRef
6.
go back to reference Massidda B, et al. Usefulness of pyridinium crosslinks and CA 15–3 as markers in metastatic bone breast carcinoma. Anticancer Res. 1996;16:2221–3.PubMed Massidda B, et al. Usefulness of pyridinium crosslinks and CA 15–3 as markers in metastatic bone breast carcinoma. Anticancer Res. 1996;16:2221–3.PubMed
7.
go back to reference Lipton A, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem. 1993;39:614–8.PubMed Lipton A, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem. 1993;39:614–8.PubMed
8.
go back to reference Izumi M, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer. 2001;91:1487–93.PubMedCrossRef Izumi M, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer. 2001;91:1487–93.PubMedCrossRef
9.
go back to reference Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget’s disease of bone. J Clin Endocrinol Metab. 1984;58:110–20.PubMedCrossRef Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL. Serum levels of type I and III procollagen fragments in Paget’s disease of bone. J Clin Endocrinol Metab. 1984;58:110–20.PubMedCrossRef
10.
go back to reference Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone. 2000;26:241–7.PubMedCrossRef Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone. 2000;26:241–7.PubMedCrossRef
11.
go back to reference Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998;63:102–6.PubMedCrossRef Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 1998;63:102–6.PubMedCrossRef
12.
go back to reference Blumsohn A, et al. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab. 1994;79:730–5.PubMedCrossRef Blumsohn A, et al. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab. 1994;79:730–5.PubMedCrossRef
13.
go back to reference Lipton A, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193–201.PubMedCrossRef Lipton A, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113:193–201.PubMedCrossRef
14.
go back to reference Coleman RE, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–35.PubMedCrossRef Coleman RE, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925–35.PubMedCrossRef
15.
go back to reference De Marinis F, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280–8.PubMedCrossRef De Marinis F, et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 2009;4:1280–8.PubMedCrossRef
16.
go back to reference Yun HK, et al. Laboratory evaluation of bone marrow metastasis: single institute study. Korean J Lab Med. 2007;27:96–101.PubMedCrossRef Yun HK, et al. Laboratory evaluation of bone marrow metastasis: single institute study. Korean J Lab Med. 2007;27:96–101.PubMedCrossRef
17.
go back to reference Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci. 1994;31:197–293.PubMedCrossRef Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci. 1994;31:197–293.PubMedCrossRef
Metadata
Title
Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer
Authors
Motohiro Tamiya
Hidekazu Suzuki
Masashi Kobayashi
Shinji Sasada
Norio Okamoto
Naoko Morishita
Tomomi Yasue
Yuka Matsuura
Tomonori Hirashima
Ichiro Kawase
Publication date
01-03-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9801-z

Other articles of this Issue 1/2012

Medical Oncology 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.